Abstract 1497
Background
We report an analysis of Asian vs non-Asian pts with CRZ-refractory, ALK+ NSCLC from ALTA (NCT02094573).
Methods
Pts were stratified by presence of baseline (BL) CNS metastases and best response to prior CRZ and randomized 1:1 to BRG 90 mg qd (arm A) or 180 mg qd with a 7-day lead-in at 90 mg (arm B). Primary endpoint: Investigator-assessed confirmed ORR by RECIST v1.1.
Results
222 pts were randomized; 69 Asian (A/B, n = 39/30), 153 non-Asian (n = 73/80); median age: Asian, 50/56 y; non-Asian, 51/57 y; 85/70% vs 64/66% had BL CNS metastases. As of Sep 2017, median follow-up was 18.4/22.5 mo (A/B) in Asians vs 22.3/24.5 mo in non-Asians. In Asians, median IRC-assessed PFS (mo) was 9.1 (95% CI 5.6–18.2) in A vs 15.6 (9.2–21.2) in B (HR 0.88 [95% CI 0.48–1.62]; P = 0.6808); in non-Asians, PFS (A/B) was 9.9 (9.0–26.3) vs 17.9 (11.6–23.9; HR 0.72 [0.45–1.13]; P = 0.1510) (Table). Of 7/2 (A/B) Asian pts with measurable BL CNS metastases, 3/1 had confirmed intracranial objective responses; in non-Asian pts with measurable BL CNS metastases, IRC-assessed iORR was 53/69% (n = 19/16). In Asians (A vs B) with any BL CNS metastases, IRC-assessed median iPFS (mo) was 15.6 (5.6–18.4) vs 12.8 (7.3–21.1); in non-Asians, 12.8 (7.4–NR) vs 20.7 (11.1–NR). Most common any-grade TRAEs in Asians (≥20%): increased CPK and amylase; in non-Asians, nausea, diarrhea, and increased CPK. Most common grade ≥3 TRAEs (>3%) in Asians: increased CPK; in non-Asians, increased CPK and lipase, hypertension. Early-onset pulmonary AEs occurred in 3 (4%; 1 grade ≥3) Asian (Korean) and 11 (7%; 6 grade ≥3) non-Asian pts. Dose reductions due to AE: 7.7/30.0% in Asian pts; 7.1/28.8% in non-Asian pts; discontinuations due to AE: 7.7/16.7% in Asian pts; 10.0/20.0% in non-Asian pts.Table:
1543P
Investigator-Assessed | Independent Review Committee (IRC)–Assessed | |||||||
---|---|---|---|---|---|---|---|---|
Asian (n = 69) | Non-Asian (n = 153) | Asian (n = 69) | Non-Asian (n = 153) | |||||
Arm A (n = 39) | Arm B (n = 30) | Arm A (n = 73) | Arm B (n = 80) | Arm A (n = 39) | Arm B (n = 30) | Arm A (n = 73) | Arm B (n = 80) | |
Confirmed ORR, % | 49 (30–67a) | 67 (45–84a) | 44 (31–58a) | 53 (40–65a) | 56 (40–72b) | 67 (47–83b) | 48 (36–60b) | 53 (41–64b) |
Median DoR in responders,c mo | 13.7 (5.6–19.4b) | 13.8 (10.2–14.8b) | 9.5 (7.4–NRb) | 16.6 (9.0–24.0b) | 16.4 (5.6–24.9b) | 13.9 (7.4–19.4b) | 24.6 (7.4–NRb) | 15.7 (12.6–30.2b) |
Median PFS,c mo Events, % | 9.2 (5.6–15.6b) 69 | 15.6 (11.1–15.7b) 60 | 9.2 (5.7–11.1b) 69 | 14.7 (10.8–24.0b) 58 | 9.1 (5.6–18.2b) 67 | 15.6 (9.2–21.2b) 60 | 9.9 (9.0–26.3b) 53 | 17.9 (11.6–23.9b) 45 |
OSc Median, mo 1-y,c % 2-y,c % | NR (18.2–NRb) 77 (60–88b) 56 (37–72b) | NR (NR–NRb) 92 (73–98b) 79 (57–91b) | 29.5 (14.5–NRb) 67 (54–76b) 53 (41–64b) | 34.1 (22.6–NRb) 76 (65–84b) 62 (50–71b) | – – – | – – – | – – – | – – – |
DoR, duration of response; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. a97.5% CI (primary endpoint); b95% CI; cKaplan-Meier estimate.
Conclusions
BRG showed comparable efficacy and acceptable safety in Asians and non-Asians in CRZ-refractory ALK+ NSCLC, with nonsignificant, numerically improved PFS at the 180-mg (with lead-in) dose.
Clinical trial identification
NCT02094573.
Editorial acknowledgement
Peloton Advantage, LLC, an OPEN Health Company, funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Legal entity responsible for the study
ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding
ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Disclosure
D.H. Lee: Honoraria (self): AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ChongKunDang, CJ Healthcare, Eli Lilly, Genexine, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, Takeda. D. Kim: Research grant / Funding (institution): Alpha Biopharma, Astrazeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan. D.R. Camidge: Honoraria (self): AstraZeneca, Takeda, Genoptix, G1 Therapeutics [DSMB], Mersana Therapeutics, Roche, Ignyta, Daiichi Sankyo [ILD adjudication committee], Hansoh SRC, Bio-Thera DSMB, Lycera, Revolution Med; Research grant / Funding (self): Takeda. C.J. Langer: Honoraria (self): Bristol-Myers Squibb, Eli Lilly, Roche/Genentech; Advisory / Consultancy: Abbott, ARIAD, AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Cancer Support Community, Celgene, Clarient, Clovis Oncology, Eli Lilly, Merck, Roche/Genentech, Takeda; Research grant / Funding (self): Advantagene, ARIAD, Celgene, Clovis Oncology, GlaxoSmithKline, Inovio, Merck, Roche/Genentech, Stemcentrx; Advisory / Consultancy: Amgen, Lilly, Peregrine Pharmaceuticals, Synta. R.M. Huber: Honoraria (self): ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Roche; Advisory / Consultancy: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Novartis, Roche; Research grant / Funding (self): Pierre Fabre. M. Tiseo: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Roche. H.L. West: Advisory / Consultancy: AbbVie, ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck, PharmaMar, Roche/Genentech, Spectrum, Takeda; Speaker Bureau / Expert testimony: ARIAD, Bristol-Myers Squibb, Roche/Genentech. H.J.M. Groen: Advisory / Consultancy: AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Research grant / Funding (self): Eli Lilly, Roche. K.L. Reckamp: Advisory / Consultancy: Amgen, ARIAD, Astellas, Takeda, Tesaro; Research grant / Funding (self): Adaptimmune, ARIAD, BMS, Boehringer Ingelheim, AbbVie, Novartis, Pfizer, Roche/Genentech, Xcovery. M.J. Hochmair: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, Takeda; Advisory / Consultancy: Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Roche, Takeda. N.B. Leighl: Travel / Accommodation / Expenses: AstraZeneca, BMS, MSD, Pfizer. K.H. Hansen: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Roche; Advisory / Consultancy: AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Roche; Travel / Accommodation / Expenses: BMS, Boehringer Ingelheim, MSD, Pfizer, Roche. S.N. Gettinger: Advisory / Consultancy: Alexion Pharmaceuticals, ARIAD, Bristol-Myers Squibb, Pfizer; Research grant / Funding (self): ARIAD, Bristol-Myers Squibb, Incyte, Pfizer, Roche/Genentech. L. Paz-Ares: Honoraria (self), Spouse / Financial dependant: Eli Lilly, MSD, BMS, Roche, PharmaMar, Merck, AstraZeneca, Novartis, Boehringer Ingelheim, Celgene, Servier, Sysmex, Amgen, Incyte, Pfizer, Ipsen, Adacap, Sanofi, Bayer, Blueprint; Officer / Board of Directors: Genomica; Research grant / Funding (institution): MSD, BMS, AstraZeneca, Pfizer. E.S. Kim: Advisory / Consultancy: AstraZeneca, Celgene, Eli Lilly; Honoraria (self): Eli Lilly, AstraZeneca, Celgene. E.F. Smit: Advisory / Consultancy: Eli Lilly; Research grant / Funding (self): AstraZeneca, Bayer, Boehringer Ingelheim, Roche/Genentech. Q. Ni: Full / Part-time employment: Takeda. P. Zhang: Full / Part-time employment: Takeda. M. Ahn: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, MSD; Advisory / Consultancy: AstraZeneca, Boehringer Ingelheim, Lilly, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
5519 - Is there a difference of Palliative care problems and needs between cancer and non-cancer hospitalized elderly patients?
Presenter: Ioanna Chatzi
Session: Poster Display session 1
Resources:
Abstract
2505 - There is a lack of clinical research for patients with cancer in palliative care
Presenter: Marie Vinches
Session: Poster Display session 1
Resources:
Abstract
5273 - Specialist Palliative Care (SPC) in Haematological Malignancy: Establishing practices in a UK Tertiary Cancer Centre (TCC)
Presenter: Emma Kedgley
Session: Poster Display session 1
Resources:
Abstract
5864 - Evaluation of the relationship between the attachment styles and psychological resilience of cancer patients receiving chemotherapy
Presenter: Fatma Bugdayci Basal
Session: Poster Display session 1
Resources:
Abstract
770 - Gefitinib along with Methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
Presenter: Vidya Dusi
Session: Poster Display session 1
Resources:
Abstract
4232 - High intensity end-of-life care in pediatrics, adolescent and young adult patients with cancer using an administrative database.
Presenter: Seiko Bun
Session: Poster Display session 1
Resources:
Abstract
4845 - Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Presenter: Deniz Can Guven
Session: Poster Display session 1
Resources:
Abstract
3270 - Internet-based stepped care for individuals with cancer and concurrent anxiety or depression symptoms – results from a randomized controlled trial
Presenter: Birgitta Johansson
Session: Poster Display session 1
Resources:
Abstract
5503 - Impact of Cognitive-Behavioral-Therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)
Presenter: Daniela Tregnago
Session: Poster Display session 1
Resources:
Abstract
5553 - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care
Presenter: Daniel Pequeno
Session: Poster Display session 1
Resources:
Abstract